Sepsis is an increasingly com-mon and lethal condition among hospitalized patients. It
remains one of the most difficult conditions we encounter as intensivists, in part because of …

With the discovery almost 25 years ago that administration of tumor necrosis factor-α could
produce shock and tissue injury similar to severe sepsis, the fundamental role for cytokines …

Sepsis affects approximately 1,750,000 people in the United States each year with half
requiring ICU admission and 20–30% of cases resulting in death (1). Among those who …

Iread with interest the article by Abu-Kaf et al (1) published in a recent issue of Critical Care
Medicine about longterm survival of severe sepsis at ICU admission, showing 6-month, 1 …

In this issue of Critical Care Med-icine, Dr. Wiedermann and col-leagues (1) performed a
retrospective analysis of the phase III Kybersept trial and demonstrated a beneficial effect of …

Sepsis is an increasingly com-mon and lethal condition among hospitalized patients. It
remains one of the most difficult conditions we encounter as intensivists, in part because of …

Cardiogenic shock is one of the most challenging and lethal clinical situations in modern
cardiovascular medicine. For generations, its grave outcome has perplexed physicians all …

We thank Salluh and Póvoa (1) for their interest in our study (2). The idea to propose C-
reactive protein (CRP) as a marker to guide antibiotic therapy in patients with sepsis came …

Human sepsis reflects a com-plex systemic process in which alterations occur in every
metabolic and regulatory system that has been studied (1). Clinical data demonstrate …

In a position statement, Carlet et al.(1) elegantly discuss the difficulty in using the current
concept of sepsis for future clinical trials and propose two new strategies. They conclude that …